Keytruda should lose stomach cancer indication, says ODACThe FDA’s Oncologic Drugs Advisory Committee (ODAC) has voted to strip Merck & Co’s Keytruda of its accelerated Share XKeytruda should lose stomach cancer indication, says ODAChttps://pharmaphorum.com/news/keytruda-should-lose-stomach-cancer-indication-says-odac/
Merck looks at M&A deals as COVID hits sales in Q1Ken Frazier’s final appearance on Merck & Co’s financial results call as chief executive was a muted affair, as Share XMerck looks at M&A deals as COVID hits sales in Q1https://pharmaphorum.com/news/merck-looks-at-ma-deals-as-covid-hits-sales-in-q1/
Merck’s Keytruda demonstrates adjuvant use in kidney cancerMerck & Co has announced interim data from its pivotal Phase 3 KEYNOTE-564 trial evaluating immunotherapy Keytruda for Share XMerck’s Keytruda demonstrates adjuvant use in kidney cancerhttps://pharmaphorum.com/news/mercks-keytruda/
NICE axes funding for MSD’s Keytruda in bladder cancer despite appealNICE has axed funding for MSD’s Keytruda for second-line advanced bladder cancer in final guidance, despite an appeal Share XNICE axes funding for MSD’s Keytruda in bladder cancer despite appealhttps://pharmaphorum.com/news/nice-axes-funding-for-msds-keytruda-in-bladder-cancer-despite-appeal/
Merck & Co axes Keytruda lung cancer niche amid FDA crackdownMerck & Co has voluntarily withdrawn its Keytruda immunotherapy from a lung cancer niche in the US, amid Share XMerck & Co axes Keytruda lung cancer niche amid FDA crackdownhttps://pharmaphorum.com/news/merck-co-axes-keytruda-lung-cancer-niche-amid-fda-crackdown/
Merck gets a leg-up for Keytruda in first-line kidney cancerNew phase 3 data have shored up the position of Merck & Co’s cancer immunotherapy Keytruda in the Share XMerck gets a leg-up for Keytruda in first-line kidney cancerhttps://pharmaphorum.com/news/merck-gets-a-leg-up-for-keytruda-in-first-line-kidney-cancer/
NICE backs NHS funding for MSD’s Keytruda combination in lung cancerNICE has backed regular NHS funding England and Wales for Merck, Sharp and Dohme’s Keytruda in combination with Share XNICE backs NHS funding for MSD’s Keytruda combination in lung cancerhttps://pharmaphorum.com/news/nice-backs-nhs-funding-for-msds-keytruda/
Ex-Merck & Co scientist accused of stealing trade secrets could face jailA former Merck & Co scientist could face up to 10 years in prison after he was accused Share XEx-Merck & Co scientist accused of stealing trade secrets could face jailhttps://pharmaphorum.com/news/merck-co-scientist-accused-of-stealing-trade-secrets-could-face-jail/
Genprex cancer gene therapy paired with AZ, Merck lung cancer drugsAn experimental gene therapy developed by Texas biotech Genprex will be paired with AstraZeneca’s Tagrisso and Merck & Share XGenprex cancer gene therapy paired with AZ, Merck lung cancer drugshttps://pharmaphorum.com/news/genprex-cancer-gene-therapy-paired-with-az-merck-lung-cancer-drugs/
